CD274 and neoplasm: Therefore, the TIDE score can integrate these two mechanisms of tumor immune escape better than widely used biomarkers (tumor mutation load, PD-L1 levels, and interferon γ) for evaluating the efficacy of immune checkpoint suppressive therapies.